Achillion Pharmaceuticals Inc.’s cash drain accelerated in the second quarter as the New Haven drug developer continues herding several treatments for hepatitis C and other blood-borne ailments through its pipeline toward regulatory approvals.
For three months ended June 30, Achillion lost a net $19.9 million, or 21 cents a share, up from $11.5 million, or 16 cents a share, lost the same quarter a year ago.
Achillion didn’t have revenues in either quarter.
The company had $187.4 million in cash and equivalents at June 30.
